Stay alert, beware of scamsters - know more

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open215.91
High219.99
Low203.35
Prev. Close205.51
Avg. Traded Price209.35
Volume2,71,546

MARKET DEPTH

info2
Total bid44.00
Total ask0.00
OrdersQtyBid
444205.51
000
000
000
000
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

215.022 days ago
225.25a day ago
arrow

LOWER/UPPER CIRCUITS

178.05
267.07
arrow
Artemis Medicare Services Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 9.48%, in the last year to ₹969.9 Cr. Its sector's average revenue growth for the last fiscal year was 16.32%.
noteAnnual Net Profit,rose 68.14% in the last year to ₹82.63 Cr. Its sector's average net profit growth for the last fiscal year was 90.21%.
notePrice to Earning Ratio,is 36.74, lower than its sector PE ratio of 53.52.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : %
Net profit growth 5Y CAGR : %

About Artemis Medicare Services Limited

 

Artemis Medicare Services Limited is a healthcare services company incorporated in 2004, with its Registered Office in Dwarka, Delhi, and Corporate Office at Artemis Hospital, Sector-51, Gurugram, Haryana. The company’s flagship unit, Artemis Hospital in Gurugram, was established in 2007 as a multi-specialty facility and became the first hospital in the city to be accredited by both Joint Commission International (JCI), USA, and the National Accreditation Board for Hospitals & Healthcare Providers (NABH), underscoring its focus on quality and patient safety. Artemis provides a comprehensive suite of inpatient and outpatient services spanning high-end medical and surgical disciplines, supported by quaternary and super-speciality care capabilities.

 

The company serves patients from India and abroad and has strengthened its position in Medical Value Travel, with international patients contributing significantly to performance. As at March 31, 2025, Artemis reported one subsidiary; the company does not have any material subsidiary under the applicable policy framework. Recent milestones include the inauguration of a third tower at the Gurugram campus towards the end of Q2FY25—part of a phased ramp-up to meet growing demand—and the achievement of the highest-ever ARPOB alongside strong EBITDA margins, reflecting operating scale and efficiency. The company has also articulated expansion plans across Delhi NCR and select Tier 2 cities via brownfield and greenfield models, and has signed a long-term Operations & Management and Medical Services Agreement for a 300+ bed super speciality hospital in Raipur, Chhattisgarh, expected to become operational in FY 2025-26.

 

Artemis Medicare Services Limited Business Segments

 

  • By service (Standalone, FY 2024-25): Healthcare & Other Services 97.39%; Pharmacy Drugs & Medical Consumables 2.61%. These ratios are derived from the company’s disaggregated revenue disclosures for the year.
  • By geography (Standalone, FY 2024-25): India 72.16%; Outside India 27.84%, based on the reported split of revenue by location of customers.

 

Artemis Medicare Services Limited Key Management

 

  • Onkar Kanwar – Chairman and Non-Executive Director
  • Dr. Devlina Chakravarty – Managing Director
  • Sanjiv Kumar Kothari – Chief Financial Officer
  • Poonam Makkar – Company Secretary

 

Latest Updates on Artemis Medicare Services Limited

 

  • Capacity expansion: The company inaugurated its third tower at the Gurugram facility towards the end of Q2FY25; the tower is being operationalised in phases to support rising patient volumes. During the year, Artemis delivered its strongest operational performance to date, with record ARPOB and robust EBITDA margins as scale and efficiency improved.
  • Growth capital infusion: Artemis raised Rs. 330 crore from International Finance Corporation (IFC) through Compulsorily Convertible Debentures (CCDs) to fund expansion in quaternary and super-speciality care under brownfield and greenfield models across Delhi NCR and Tier 2 cities. The company received in-principle approvals from BSE and NSE on May 7, 2024, for the issuance of up to 1,89,62,247 equity shares upon conversion; the CCDs are convertible within 18 months from allotment, with a conversion price of Rs. 174.03 per equity share. As on March 31, 2025, 33,000 unsecured CCDs of Rs. 1,00,000 each held by IFC remained outstanding, convertible on or before November 15, 2025.
  • Expansion of footprint: The company entered into a Long-Term Operations & Management and Medical Services Agreement to run a 300+ bed super speciality hospital in Raipur, Chhattisgarh, targeted to be operational in FY 2025-26, marking a meaningful entry into Central India.
  • Technology and patient-care initiatives: Artemis launched advanced technology-enabled physiotherapy services in partnership with Abhinav Bindra Targeting Performance (ABTP), aimed at personalised, high-performance rehabilitation. It also initiated the replacement of its Hospital Information System to streamline workflows, data management, billing and analytics, and implemented a strengthened patient feedback mechanism to improve the hospital journey.
personal

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

Artemis Hospital, the company’s flagship unit in Gurugram, was established in 2007 and is the first in the city with both JCI and NABH accreditations, reflecting internationally benchmarked standards.

As at March 31, 2025, the company had one subsidiary; there is no material subsidiary as per its policy on material subsidiaries.

Key developments included inaugurating a third tower at the Gurugram campus, raising Rs. 330 crore via IFC CCDs (with stock exchange in-principle approvals on May 7, 2024), an O&M agreement for a 300+ bed hospital in Raipur, and a partnership with ABTP for technology-enabled physiotherapy services.